RGNX
Price
$13.88
Change
+$1.03 (+8.02%)
Updated
Dec 12, 04:59 PM (EDT)
Capitalization
650.51M
81 days until earnings call
Intraday BUY SELL Signals
SAVA
Price
$3.15
Change
-$0.11 (-3.37%)
Updated
Dec 11 closing price
Capitalization
152.17M
81 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RGNX vs SAVA

Header iconRGNX vs SAVA Comparison
Open Charts RGNX vs SAVABanner chart's image
REGENXBIO
Price$13.88
Change+$1.03 (+8.02%)
Volume$13.23K
Capitalization650.51M
Cassava Sciences
Price$3.15
Change-$0.11 (-3.37%)
Volume$652.15K
Capitalization152.17M
RGNX vs SAVA Comparison Chart in %
View a ticker or compare two or three
VS
RGNX vs. SAVA commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Hold and SAVA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (RGNX: $12.85 vs. SAVA: $3.15)
Brand notoriety: RGNX and SAVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 97% vs. SAVA: 40%
Market capitalization -- RGNX: $650.51M vs. SAVA: $152.17M
RGNX [@Biotechnology] is valued at $650.51M. SAVA’s [@Biotechnology] market capitalization is $152.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $113.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileSAVA’s FA Score has 1 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • SAVA’s FA Score: 1 green, 4 red.
According to our system of comparison, both RGNX and SAVA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 3 TA indicator(s) are bullish while SAVA’s TA Score has 3 bullish TA indicator(s).

  • RGNX’s TA Score: 3 bullish, 6 bearish.
  • SAVA’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than SAVA.

Price Growth

RGNX (@Biotechnology) experienced а -1.00% price change this week, while SAVA (@Biotechnology) price change was -5.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

RGNX is expected to report earnings on Mar 03, 2026.

SAVA is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($651M) has a higher market cap than SAVA($152M). RGNX YTD gains are higher at: 66.235 vs. SAVA (38.136). RGNX (-129.93M) and SAVA (-129.96M) have comparable annual earnings (EBITDA) . RGNX has more cash in the bank: 323M vs. SAVA (112M). SAVA has less debt than RGNX: SAVA (0) vs RGNX (77.7M). RGNX has higher revenues than SAVA: RGNX (156M) vs SAVA (0).
RGNXSAVARGNX / SAVA
Capitalization651M152M428%
EBITDA-129.93M-129.96M100%
Gain YTD66.23538.136174%
P/E RatioN/AN/A-
Revenue156M0-
Total Cash323M112M288%
Total Debt77.7M0-
FUNDAMENTALS RATINGS
RGNX vs SAVA: Fundamental Ratings
RGNX
SAVA
OUTLOOK RATING
1..100
625
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
3939
P/E GROWTH RATING
1..100
19100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAVA's Valuation (24) in the Pharmaceuticals Other industry is somewhat better than the same rating for RGNX (73) in the Biotechnology industry. This means that SAVA’s stock grew somewhat faster than RGNX’s over the last 12 months.

SAVA's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as RGNX (100) in the Biotechnology industry. This means that SAVA’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (97) in the Biotechnology industry is in the same range as SAVA (98) in the Pharmaceuticals Other industry. This means that RGNX’s stock grew similarly to SAVA’s over the last 12 months.

RGNX's Price Growth Rating (39) in the Biotechnology industry is in the same range as SAVA (39) in the Pharmaceuticals Other industry. This means that RGNX’s stock grew similarly to SAVA’s over the last 12 months.

RGNX's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for SAVA (100) in the Pharmaceuticals Other industry. This means that RGNX’s stock grew significantly faster than SAVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXSAVA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 23 days ago
84%
Bearish Trend 23 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 3 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
RGNX
Daily Signal:
Gain/Loss:
SAVA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HUMDX17.820.30
+1.71%
Huber Mid Cap Value Inv
TCMSX51.100.63
+1.25%
Voya Small Cap Growth I
LAFYX20.300.13
+0.64%
Lord Abbett Affiliated I
AAWEX18.28-0.01
-0.05%
Cavanal Hill World Energy A
GCVTX24.83-1.36
-5.19%
Goldman Sachs Large Cp Val Insghts Inv

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with CRSP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
+0.62%
CRSP - SAVA
40%
Loosely correlated
+0.96%
RXRX - SAVA
39%
Loosely correlated
N/A
BEAM - SAVA
39%
Loosely correlated
+3.47%
IMNM - SAVA
38%
Loosely correlated
+6.51%
RGNX - SAVA
37%
Loosely correlated
+2.67%
More